NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024

Company Overview - Nanobiotix is a late-stage clinical biotechnology company focused on physics-based approaches to cancer treatment, headquartered in Paris, France, and listed on Euronext Paris since 2012 and on Nasdaq since December 2020 [3][7] - The company has subsidiaries in Cambridge, Massachusetts, among other locations [3] Upcoming Event - Nanobiotix will host a virtual Key Opinion Leader (KOL) event on June 18, 2024, from 9:00-10:30 AM EDT / 3:00-4:30 PM CEST [1] - The event will feature KOLs including Dr. Colette Shen, Dr. Ari Rosenberg, and Dr. Jeffrey Bockman, who will discuss NBTXR3 and its role in treating recurrent/metastatic head and neck cancer [11] Research Focus - The KOL event will cover topics such as the mechanisms of action of NBTXR3, its local and systemic responses, and the treatment landscape for head and neck cancer patients, highlighting unmet needs [12][11] - Recent data presented at the 2024 Annual Meeting of the American Society for Clinical Oncology (ASCO) will be reviewed, showing disease control and tumor response in patients treated with radiotherapy-activated NBTXR3 followed by anti-PD-1 therapy [11]